Firms invested CHF16.8 billion ($18 billion) in research and development (R&D) activities in Switzerland last year, a 4% increase compared to 2019.
This content was published on
2 minutes
FSO/Keystone-SDA/sb
A survey carried out by the Federal Statistical Office (FSO) and the Swiss Business Federation economiesuisse said the pharmaceutical sector was the biggest R&D investor (CHF6.2 billion, or 37% of the total).
The overall CHF1.3 billion rise since 2019 was in line with a recent upward trend, but it is all the more remarkable given the difficult economic situations in 2020 and 2021 caused by the Covid-19 pandemic, the FSO said in a statementExternal link on Monday.
Fundamental research fell from around one quarter of companies’ overall research investment in 2015 to 8% in 2021. This is mainly due to changes in the type of research carried out within pharmaceutical companies, the FSO said.
More
More
The end of affordable medicine
This content was published on
Pharma companies are close to a cure for cancer, but will the hefty price tags make treatments unaffordable for most of the world?
Looking at the different specialist fields, R&D investment in biotechnology has steadily increased since 2012, the statistics office said. In 2021, companies invested CHF5.9 billion in this area, or 35% of total R&D spending.
Firms invested CHF6.3 billion on R&D abroad – a slight decrease – the FSO said.
“After strong growth between 2012 and 2017, the current trend seems to show that companies are finding in Switzerland the means to meet their own R&D needs,” it said.
Last year, companies employed nearly 62,000 people working on R&D, an annual increase of 2% since 2019. A quarter of all research staff were women, a percentage that has remained the same over the past ten years.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
EU Commission president says Swiss-EU deal is ‘historic’ agreement
This content was published on
At a joint media conference with Swiss President Viola Amherd in Bern, European Commission President Ursula von der Leyen spoke of a "day of joy".
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland and UK sign major agreement on science and innovation
This content was published on
The agreement, signed by the UK and Switzerland, is to deepen ties between their respective research and innovation communities.
This content was published on
Pharma companies are close to a cure for cancer, but will the hefty price tags make treatments unaffordable for most of the world?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.